Target intelligence / Profile preview

Plasma Coagulation Factors and Endothelial Proteins

Molecular classification
Enzyme, Receptor, Protease inhibitor, Other
01

Overview

Plasma coagulation factors are a series of mostly liver-derived plasma proteins (enzymes and cofactors; e.g., fibrinogen, prothrombin, factors V, VII, VIII, IX, X, XI, XII) that participate in the coagulation cascade responsible for forming a stable blood clot following vascular injury. Endothelial proteins include both procoagulant (e.g., von Willebrand factor, tissue factor) and anticoagulant (e.g., thrombomodulin, tissue factor pathway inhibitor, endothelial protein C receptor) molecules produced or expressed by vascular endothelial cells, which regulate coagulation, prevent excessive clot formation, and maintain vascular homeostasis. The proper function and balance of these proteins is essential for normal hemostasis, and dysfunction can lead to bleeding or thrombotic disease[1][2][3][5][6][7][8]. This entry does not denote a discrete canonical molecular target and should not be treated as such. Instead, it refers to a physiological system comprising numerous interacting proteins and regulatory pathways.

Other names
Coagulation factors and endothelial regulatory proteinsBlood clotting proteins and endothelial proteins
02

Mechanism of action

Inhibition of specific coagulation factors (e.g., antithrombin activity potentiated by heparin); Vitamin K antagonism to reduce synthesis of active clotting factors; Direct inhibition of thrombin or factor Xa; Activation of plasminogen to promote fibrinolysis

03

Biological functions

Hemostasis (coagulation and fibrinolysis)Regulation of clot formationLimiting thrombus propagationEndothelial protection and vascular integrityModulation of immune response
04

Disease associations

Cardiovascular disease (thrombosis, embolism)Hemorrhagic disorders (e.g., hemophilia)Inflammation and sepsisOther (disseminated intravascular coagulation)
05

Safety considerations

Increased risk of bleeding (hemorrhage) with any anticoagulant therapyThrombotic complications if regulatory proteins are deficientRisk of heparin-induced thrombocytopeniaHypersensitivity and allergic reactions to biological products (e.g., factor concentrates)
06

Interacting drugs

Heparin and low molecular weight heparins (enoxaparin, dalteparin, tinzaparin)

4 more in the full profile.

07

Biomarkers

Prothrombin time (PT), activated partial thromboplastin time (aPTT)D-dimer (fibrin degradation product)Levels of specific factors (e.g., factor VIII, von Willebrand factor)Protein C and S levels

Beyond the preview

Go deeper on Plasma Coagulation Factors and Endothelial Proteins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasma Coagulation Factors and Endothelial Proteins.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call